Gastrointestinal Cancer

César Serrano-García, MD, discusses the rationale for the phase 3 INVICTUS trial in patients with advanced gastrointestinal stromal tumors.

Daneng Li, MD, discusses the subgroup analysis of the phase 3 IMbrave150 trial in patients with unresectable hepatocellular carcinoma.

The CXCR4 antagonist BL-8040 in combination with the PD-1 inhibitor pembrolizumab has been shown to elicit encouraging responses in patients with pancreatic ductal adenocarcinoma.

The combination therapy of dabrafenib and trametinib recently demonstrated encouraging activity and a manageable safety profile in patients with BRAF V600E–mutated biliary tract cancer.

Jeffrey A. Meyerhardt, MD, MPH, FASCO, discusses the rationale for the randomized phase 3 CALGB/SWOG 80702 trial in colon cancer.

Van K. Morris, MD, discusses the role of circulating tumor DNA in resected colon cancer.

Allyson Ocean, MD, discusses the encouraging results from the phase II TYME-88-Panc study of SM-88 in patients with advanced pancreatic cancer.

Rutika J. Mehta, MD, MPH, discusses the role of biomarkers in gastric cancer.

Bradley G. Somer, MD, discusses the impact of the phase 3 IMbrave150 trial on the treatment of patients with unresectable hepatocellular carcinoma.

The Japan Pharmaceuticals and Medical Devices Agency has approved pembrolizumab for the treatment of patients with radically unresectable, advanced, or recurrent esophageal squamous cell carcinoma whose tumors are PD-L1–positive, and at an additional recommended dosage of 400 mg every 6 weeks as an intravenous infusion across all adult indications.

Experts share insight on their clinical experience with interstitial lung disease.

Recently developed treatments for HER2-positive breast cancer, lung cancers, and gastrointestinal cancers include antibody-drug conjugates, CDK4/6 inhibitors, and immuno-oncology agents.

Bradley G. Somer, MD, discusses shifts in the hepatocellular carcinoma treatment paradigm, pivotal trials that have generated excitement, and sequencing approaches.

Thorvardur (Thor) Halfdanarson, MD, discusses novel approaches under investigation in the later-line treatment of patients with CRC.

Richard D. Kim, MD, discusses the evolving treatment landscape of HCC, the approval of atezolizumab/bevacizumab, and other pivotal data in HCC.

Noam VanderWalde, MD, MS, highlights the importance of multidisciplinary care for rectal cancer and few key studies that have impacted treatment.

Rutika J. Mehta, MD, MPH discusses key updates in gastric and gastroesophageal junction management, trials of interest, and the importance of testing for biomarkers.

Pembrolizumab in combination with chemotherapy significantly improved overall survival and progression-free survival in the frontline treatment of patients with locally advanced or metastatic esophageal cancer.

Dae Won Kim, MD, discusses the NAPOLI-1 and NAPOLI-3 trials in metastatic pancreatic cancer, as well as the role of PARP inhibitors and remaining challenges in the space.

Jordan D. Berlin, MD, discusses the importance of more data and more effective treatment regimens in metastatic pancreatic cancer, despite the number of treatment options currently available.

Anthony B. El-Khoueiry, MD, discusses the frontline treatment landscape of hepatocellular carcinoma.

Richard D. Kim, MD, discusses the evolving treatment landscape of advanced hepatocellular carcinoma.

Noam VanderWalde, MD, MS, discusses ​where future research ​efforts should focus in rectal cancer. 

Thorvardur (Thor) Halfdanarson, MD, discusses the molecular differences between left- versus right-sided tumors in colorectal cancer.

Nivolumab in combination with chemotherapy as a frontline treatment demonstrated a significant survival benefit in patients with metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma